As per the pdf enclosed
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venus Remedies has received Marketing Authorization from Saudi Food and Drug Authority (SFDA) for Plerixafor, a stem cell mobilization therapy used in autologous transplantation for multiple myeloma and non-Hodgkin lymphoma. This is the company's first Plerixafor approval globally, marking a strategic entry into higher-value specialty injectables in oncology. The approval enables commercialization of Plerixafor 24mg/1.2ml through Venus's existing international business network, targeting tertiary oncology centers in Saudi Arabia. Saudi Arabia is the largest pharmaceutical market in the GCC, projected to grow from USD 12.1 billion in 2026 to USD 17.1 billion by 2033.
This approval is positive for shareholders as it opens access to a growing regulated market with strong oncology infrastructure. It validates Venus Remedies' strategic shift from commodity injectables to differentiated specialty therapies, potentially expanding revenue streams in higher-margin product categories.